专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20050009028A1 Method for isolating cell-type specific mrnas 有权
标题翻译：分离细胞型特异性细胞的方法
公开(公告)号：US20050009028A1
公开(公告)日：2005-01-13
申请号：US10494248
申请日：2002-10-29
申请人： Nathaniel Heintz , Tito Serafini , Andrew Shyjan
发明人： Nathaniel Heintz , Tito Serafini , Andrew Shyjan
IPC分类号： C12N15/10 , C12Q1/68 , C12N1/08 , C12P19/34
CPC分类号： C12N15/1041 , C12N15/1006 , C12N15/82 , C12N15/8222 , C12Q1/6827
摘要： The invention provides methods for isolating cell-type specific mRNAs by selectively isolating ribosomes or proteins that bind mRNA in a cell type specific manner, and, thereby, the mRNA bound to the ribosomes or proteins that bind mRNA. Ribosomes, which are riboprotein complexes, bind mRNA that is being actively translated in cells. According to the methods of the invention, cells are engineered to express a molecularly tagged ribosomal protein or protein that binds mRNA by introducing into the cell a nucleic acid comprising a nucleotide sequence encoding a ribosomal protein or protein that binds mRNA fused to a nucleotide sequence encoding a peptide tag. The tagged ribosome or mRNA binding protein can then be isolated, along with the mRNA bound to the tagged ribosome or mRNA binding protein, and the mRNA isolated and further used for gene expression analysis. The methods of the invention facilitate the analysis and quantification of gene expression in the selected cell type present within a heterogeneous cell mixture, without the need to isolate the cells of that cell type as a preliminary step.
摘要翻译：本发明提供了通过选择性分离以细胞类型特异性方式结合mRNA的核糖体或蛋白质分离细胞型特异性mRNA的方法，从而提供与结合mRNA的核糖体或蛋白质结合的mRNA。作为核糖体复合物的核糖体结合正在细胞中积极翻译的mRNA。根据本发明的方法，将细胞工程化以表达分子标记的核糖体蛋白质或蛋白质，其通过向细胞中引入核酸，所述核酸包含编码核糖体蛋白质或蛋白质的核苷酸序列，所述核糖体蛋白质或蛋白质与编码肽标签。然后可以分离标记的核糖体或mRNA结合蛋白以及与标记的核糖体或mRNA结合蛋白结合的mRNA，并分离mRNA并进一步用于基因表达分析。本发明的方法促进了在异质细胞混合物中存在的所选细胞类型中的基因表达的分析和定量，而不需要将该细胞类型的细胞作为初步步骤分离。

2. 发明申请

US20050191307A1 Novel multidrug resistance-associated polypeptide 失效
标题翻译：新型多药耐药相关多肽
公开(公告)号：US20050191307A1
公开(公告)日：2005-09-01
申请号：US11104268
申请日：2005-04-11
申请人： Andrew Shyjan
发明人： Andrew Shyjan
IPC分类号： A61K38/00 , C07K14/705 , C07K16/30 , A61K39/395 , C07K16/46
CPC分类号： C07K14/705 , A01K2217/05 , A61K38/00 , C07K2319/00
摘要： Compositions and methods are disclosed for improving the effectiveness of a chemotherapeutic regimen to eradicate multidrug-resistant transformed cells from the body of a mammal, preferably from the body of a human. The present disclosure capitalizes on the discovery of a novel multidrug-resistance associated protein (MRP), herein designated MRP-β. The disclosed compositions include MRP-β nucleic acids, including probes and antisense oligonucleotides, MRP-β polypeptides and antibodies, MRP-β expressing host cells, and non-human mammals transgenic or nullizygous for MRP-β. The disclosed methods include methods for attenuating aberrant MRP-β gene expression, protein production and/or protein function. In addition, methods are disclosed for identifying and using a modulator, such as an inhibitor, of MRP-β. Preferably, the modulator is a small molecule.
摘要翻译：公开了组合物和方法，用于改善化疗方案的有效性，以根除哺乳动物体内，优选来自人体的多药耐转化细胞。本公开利用了新型多药耐药相关蛋白（MRP）的发现，这里称为MRP-β。所公开的组合物包括MRP-β核酸，包括探针和反义寡核苷酸，MRP-β多肽和抗体，表达MRP-β的宿主细胞，以及用于MRP-β的转基因或无效的非人哺乳动物。所公开的方法包括减少异常MRP-β基因表达，蛋白质产生和/或蛋白质功能的方法。此外，公开了鉴定和使用MRP-β的调节剂如抑制剂的方法。优选地，调节剂是小分子。

3. 发明授权

US06890713B1 Multidrug resistance-associated polypeptide 失效
标题翻译：多药耐药相关多肽
公开(公告)号：US06890713B1
公开(公告)日：2005-05-10
申请号：US09528031
申请日：2000-03-17
申请人： Andrew Shyjan
发明人： Andrew Shyjan
IPC分类号： A61K38/00 , C07K14/705 , C12Q1/68
CPC分类号： C07K14/705 , A01K2217/05 , A61K38/00 , C07K2319/00
摘要： Compositions and methods are disclosed for improving the effectiveness of a chemotherapeutic regimen to eradicate multidrug-resistant transformed cells from the body of a mammal, preferably from the body of a human. The present disclosure capitalizes on the discovery of a novel multidrug-resistance associated protein (MRP), herein designated MRP-β. The disclosed compositions include MRP-β nucleic acids, including probes and antisense oligonucleotides, MRP-β polypeptides and antibodies, MRP-β expressing host cells, and non-human mammals transgenic or nullizygous for MRP-β. The disclosed methods include methods for attenuating aberrant MRP-β gene expression, protein production and/or protein function. In addition, methods are disclosed for identifying and using a modulator, such as an inhibitor, of MRP-β. Preferably, the modulator is a small molecule.
摘要翻译：公开了组合物和方法，用于改善化疗方案的有效性，以根除哺乳动物体内，优选来自人体的多药耐转化细胞。本公开利用了新型多药耐药相关蛋白（MRP）的发现，这里称为MRP-β。所公开的组合物包括MRP-β核酸，包括探针和反义寡核苷酸，MRP-β多肽和抗体，表达MRP-β的宿主细胞，以及用于MRP-β的转基因或无效的非人哺乳动物。所公开的方法包括减少异常MRP-β基因表达，蛋白质产生和/或蛋白质功能的方法。此外，公开了鉴定和使用MRP-β的调节剂如抑制剂的方法。优选地，调节剂是小分子。

4. 发明授权

US6162616A Multidrug resistance-associated polypeptide 失效
标题翻译：多药耐药相关多肽
公开(公告)号：US6162616A
公开(公告)日：2000-12-19
申请号：US843459
申请日：1997-04-16
申请人： Andrew Shyjan
发明人： Andrew Shyjan
IPC分类号： A61K38/00 , C07K14/705 , C12P21/06 , C12N5/00 , C12N15/00 , C12Q1/68
CPC分类号： C07K14/705 , A01K2217/05 , A61K38/00 , C07K2319/00
摘要： Compositions and methods are disclosed for improving the effectiveness of a chemotherapeutic regimen to eradicate multidrug-resistant transformed cells from the body of a mammal, preferably from the body of a human. The present disclosure capitalizes on the discovery of a novel multidrug-resistance associated protein (MRP), herein designated MRP-.beta.. The disclosed compositions include MRP-.beta. nucleic acids, including probes and antisense oligonucleotides, MRP-.beta. polypeptides and antibodies, MRP-.beta. expressing host cells, and non-human mammals transgenic or nullizygous for MRP-.beta.. The disclosed methods include methods for attenuating aberrant MRP-.beta. gene expression, protein production and/or protein function. In addition, methods are disclosed for identifying and using a modulator, such as an inhibitor, of MRP-.beta.. Preferably, the modulator is a small molecule.
摘要翻译：公开了组合物和方法，用于改善化疗方案的有效性，以根除哺乳动物体内，优选来自人体的多药耐转化细胞。本公开利用了新型多药耐药相关蛋白（MRP）的发现，这里称为MRP-β。所公开的组合物包括MRP-β核酸，包括探针和反义寡核苷酸，MRP-β多肽和抗体，表达MRP-β的宿主细胞，以及用于MRP-β的转基因或无效的非人哺乳动物。所公开的方法包括用于减弱异常MRP-β基因表达，蛋白质产生和/或蛋白质功能的方法。此外，公开了用于鉴定和使用MRP-β的调节剂如抑制剂的方法。优选地，调节剂是小分子。

5. 发明申请

US20050100931A1 Methods and compositions for the identification and assessment of prostate cancer therapies and the diagnosis of prostate cancer 审中-公开
标题翻译：用于鉴定和评估前列腺癌疗法和前列腺癌诊断的方法和组合物
公开(公告)号：US20050100931A1
公开(公告)日：2005-05-12
申请号：US10831704
申请日：2004-04-23
申请人： Andrew Shyjan
发明人： Andrew Shyjan
IPC分类号： C07K14/47 , C12Q1/68 , G01N33/50 , G06F19/00 , G01N33/48
CPC分类号： C07K14/47 , C12Q1/6886 , C12Q2600/136 , C12Q2600/158 , G01N33/5011 , Y02A90/26 , Y10T436/143333
摘要： The invention concerns two classes of differentially regulated genes: 1) genes that are more highly expressed in prostate cancer cells treated with testosterone than in untreated prostate cancer cells; and 2) genes that are more highly expressed in prostate cancer cells treated with bicalutamide, an anti-androgenic compound, than in untreated prostate cancer cells. Disclosed are methods for selecting and monitoring the effectiveness of therapeutic agents used for the treatment of prostate cancer. Also disclosed are methods for identifying novel therapeutic agents for the treatment of prostate cancer and methods and compositions for preventing, treating, and diagnosing prostate cancer.
摘要翻译：本发明涉及两类差异调节基因：1）在用睾酮治疗的前列腺癌细胞中比在未经治疗的前列腺癌细胞中更高表达的基因; 和2）在用比卡鲁匹丁治疗的前列腺癌细胞中抗原雄激素化合物比在未经治疗的前列腺癌细胞中更高表达的基因。公开了用于选择和监测用于治疗前列腺癌的治疗剂的有效性的方法。还公开了用于鉴定用于治疗前列腺癌的新型治疗剂的方法以及用于预防，治疗和诊断前列腺癌的方法和组合物。

6. 发明授权

US5994130A Multidrug resistance-associated polypeptide 失效
标题翻译：多药耐药相关多肽
公开(公告)号：US5994130A
公开(公告)日：1999-11-30
申请号：US1273
申请日：1997-12-31
申请人： Andrew Shyjan
发明人： Andrew Shyjan
IPC分类号： A61K38/00 , C07K14/705 , C12N15/10 , C12N15/12 , C12N15/63
CPC分类号： C07K14/705 , A01K2217/05 , A61K38/00 , C07K2319/00
摘要： Compositions and methods are disclosed for improving the effectiveness of a chemotherapeutic regimen to eradicate multidrug-resistant transformed cells from the body of a mammal, preferably from the body of a human. The present disclosure capitalizes on the discovery of a novel multidrug-resistance associated protein (MRP), herein designated MRP-.beta.. The disclosed compositions include MRP-.alpha. nucleic acids, including probes and antisense oligonucleotides, MRP-.beta. polypeptides and antibodies, MRP-.beta. expressing host cells, and non-human mammals transgenic or nullizygous for MRP-.beta.. The disclosed methods include methods for attenuating aberrant MRP-.beta. gene expression, protein production and/or protein function. In addition, methods are disclosed for identifying and using a modulator, such as an inhibitor, of MRP-.beta.. Preferably, the modulator is a small molecule.
摘要翻译：公开了组合物和方法，用于改善化疗方案的有效性，以根除哺乳动物体内，优选来自人体的多药耐转化细胞。本公开利用了新型多药耐药相关蛋白（MRP）的发现，这里称为MRP-β。所公开的组合物包括MRP-α核酸，包括探针和反义寡核苷酸，MRP-β多肽和抗体，表达MRP-β的宿主细胞，以及用于MRP-β的转基因或无效的非人哺乳动物。所公开的方法包括用于减弱异常MRP-β基因表达，蛋白质产生和/或蛋白质功能的方法。此外，公开了用于鉴定和使用MRP-β的调节剂如抑制剂的方法。优选地，调节剂是小分子。

7. 发明申请

US20130030039A1 NOVEL MULTIDRUG RESISTANCE-ASSOCIATED POLYPEPTIDE 审中-公开
标题翻译：新型多重耐药相关多糖
公开(公告)号：US20130030039A1
公开(公告)日：2013-01-31
申请号：US13618941
申请日：2012-09-14
申请人： Andrew Shyjan
发明人： Andrew Shyjan
IPC分类号： A61K31/713 , A61P35/00
CPC分类号： C07K14/705 , A01K2217/05 , A61K38/00 , C07K2319/00
摘要： Compositions and methods are disclosed for improving the effectiveness of a chemotherapeutic regimen to eradicate multidrug-resistant transformed cells from the body of a mammal, preferably from the body of a human. The present disclosure capitalizes on the discovery of a novel multidrug-resistance associated protein (MRP), herein designated MRP-β. The disclosed compositions include MRP-β nucleic acids, including probes and antisense oligonucleotides, MRP-β polypeptides and antibodies, MRP-β expressing host cells, and non-human mammals transgenic or nullizygous for MRP-β. The disclosed methods include methods for attenuating aberrant MRP-β gene expression, protein production and/or protein function. In addition, methods are disclosed for identifying and using a modulator, such as an inhibitor, of MRP-β. Preferably, the modulator is a small molecule.
摘要翻译：公开了组合物和方法，用于改善化疗方案的有效性，以根除哺乳动物体内，优选来自人体的多药耐转化细胞。本公开利用了新型多药耐药相关蛋白（MRP）的发现，这里称为MRP-＆bgr。所公开的组合物包括MRP- 核酸，包括探针和反义寡核苷酸，MRP-＆bgr; 多肽和抗体，MRP-＆bgr; 表达宿主细胞，非人哺乳动物转基因或无效MRP-＆bgr。所公开的方法包括用于减弱异常MRP-＆bgr的方法; 基因表达，蛋白质产生和/或蛋白质功能。此外，公开了用于鉴定和使用MRP-＆bgr的调节剂如抑制剂的方法。优选地，调节剂是小分子。

8. 发明申请

US20050106600A1 Compositions and methods for the diagnosis, prevention and treatment of tumor progression 审中-公开
标题翻译：用于诊断，预防和治疗肿瘤进展的组合物和方法
公开(公告)号：US20050106600A1
公开(公告)日：2005-05-19
申请号：US10932819
申请日：2004-09-01
申请人： Andrew Shyjan
发明人： Andrew Shyjan
IPC分类号： A61K38/00 , C07K14/82 , C12N15/10 , C12N15/12 , C12Q1/68 , C07H21/04 , C12N9/64
CPC分类号： C07K14/82 , A01K2217/05 , A01K2217/075 , A61K38/00 , C12N15/1034 , C12N15/1072
摘要： The present invention relates to methods and compositions for the diagnosis, prevention, and treatment of tumor progression in cells involved in human tumors such as melanomas, breast, gastrointestinal, lung, and bone tumors, various types of skin cancers, and other neoplastic conditions such as leukemias and lymphomas. Genes are identified that are differentially expressed in benign (e.g., non-malignant) tumor cells relative to malignant tumor cells exhibiting a high metastatic potential. Genes are also identified via the ability of their gene products to interact with gene products involved in the progression to, and/or aggressiveness of, neoplastic tumor disease states. The genes and gene products identified can be used diagnostically or for therapeutic intervention.
摘要翻译：本发明涉及用于诊断，预防和治疗涉及人肿瘤的细胞如黑素瘤，乳腺癌，胃肠道，肺癌和骨肿瘤，各种类型的皮肤癌和其它肿瘤病症中的肿瘤进展的方法和组合物作为白血病和淋巴瘤。鉴定出相对于表现出高转移潜能的恶性肿瘤细胞，在良性（例如，非恶性）肿瘤细胞中差异表达的基因。基因也通过其基因产物与涉及肿瘤肿瘤疾病状态进展和/或侵袭性的基因产物相互作用的能力来鉴定。鉴定的基因和基因产物可用于诊断或治疗干预。

9. 发明授权

US6077936A Multidrug resistance-associated polypeptide 失效
公开(公告)号：US6077936A
公开(公告)日：2000-06-20
申请号：US61400
申请日：1998-04-16
申请人： Andrew Shyjan
发明人： Andrew Shyjan
IPC分类号： A61K38/00 , C07K14/705 , C07K1/00 , C07H21/02 , C12Q1/68
CPC分类号： C07K14/705 , A01K2217/05 , A61K38/00 , C07K2319/00
摘要： Compositions and methods are disclosed for improving the effectiveness of a chemotherapeutic regimen to eradicate multidrug-resistant transformed cells from the body of a mammal, preferably from the body of a human. The present disclosure capitalizes on the discovery of a novel multidrug-resistance associated protein (MRP), herein designated MRP-.beta.. The disclosed compositions include MRP-.beta. nucleic acids, including probes and antisense oligonucleotides, MRP-.beta. polypeptides and antibodies, MRP-.beta. expressing host cells, and non-human mammals transgenic or nullizygous for MRP-.beta.. The disclosed methods include methods for attenuating aberrant MRP-.beta. gene expression, protein production and/or protein function. In addition, methods are disclosed for identifying and using a modulator, such as an inhibitor, of MRP-.beta.. Preferably, the modulator is a small molecule.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式